PBMs’ Impact On Drug Prices Probed By House Committee Leaders
Letter to seven pharmacy benefit managers seeks insight into pros and cons of practices, suggesting that policymakers understand PBMs bring value in lowering costs but that some activities are counterproductive.
You may also be interested in...
Policy exempts indications covered by protected classes policy, including cancer treatments.
Upcoming proposed rule could also provide new anti-kickback safe harbor to facilitate value-based contracts, as manufacturers and payers have urged.